Carcinoid Heart Disease

Cardiac manifestation of gastrointestinal CARCINOID TUMOR that metastasizes to the liver. Substances secreted by the tumor cells, including SEROTONIN, promote fibrous plaque formation in ENDOCARDIUM and its underlying layers. These deposits cause distortion of the TRICUSPID VALVE and the PULMONARY VALVE eventually leading to STENOSIS and valve regurgitation.

Also Known As:

Networked: 69 relevant articles (0 outcomes, 5 trials/studies)

Disease Context: Research Results

Related Diseases

1.	Neoplasm Metastasis (Metastasis)
2.	Carcinoid Tumor (Carcinoid)
3.	Flushing
4.	Neoplasms (Cancer)
5.	Heart Valve Diseases (Valvular Heart Disease)

Experts

1.	Bhattacharyya, Sanjeev: 4 articles (05/2013 - 02/2008)
2.	Toumpanakis, Christos: 4 articles (05/2013 - 02/2008)
3.	Davar, Joseph: 4 articles (05/2013 - 02/2008)
4.	Cuthbertson, D J: 3 articles (10/2014 - 09/2010)
5.	Thiis-Evensen, Espen: 3 articles (03/2013 - 01/2009)
6.	Vatn, Morten: 3 articles (03/2013 - 01/2009)
7.	Caplin, Martyn Evan: 3 articles (04/2011 - 02/2008)
8.	Pritchard, D M: 2 articles (10/2014 - 04/2014)
9.	Burgess, M I: 2 articles (10/2014 - 04/2014)
10.	Dobson, R: 2 articles (10/2014 - 04/2014)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Carcinoid Heart Disease:

1.	Serotonin (5 Hydroxytryptamine)IBA 03/29/2005 - "This study demonstrates that serotonin most likely is involved in the pathogenesis of carcinoid heart disease." 03/29/2005 - "The purpose of this study was to investigate whether rats dosed with serotonin develop changes similar to those seen in human carcinoid heart disease. " 01/01/2015 - "It is important to follow serotonin levels since the elevated levels of serotonin can cause carcinoid heart disease. " 10/01/2013 - "Carcinoid heart disease is a rare cause of right-sided valvular dysfunction, primarily mediated by serotonin. " 05/01/2013 - "Circulating plasma and platelet 5-hydroxytryptamine in carcinoid heart disease: a pilot study."
2.	pro-brain natriuretic peptide (1-76)IBA 09/10/2009 - "This study examined the diagnostic value of CgA and NT-proBNP for carcinoid heart disease (CHD), and their prognostic value for overall survival in NET patients. " 01/01/2013 - "NT-proBNP and plasma 5HIAA had the highest areas under the curve for the prediction of carcinoid heart disease [NT-proBNP 0.82 (95% confidence interval 0.74-0.90, p<0.0001) and 5HIAA 0.85 (95% confidence interval 0.78-0.92, p<0.0001]. " 01/01/2013 - "NT-proBNP and plasma 5HIAA are both sensitive and specific biomarkers for the presence of carcinoid heart disease whereas only NT-proBNP is moderately correlated with disease severity."
3.	Endothelin Receptors (Endothelin Receptor)IBA 01/01/2010 - "The primary aim of this study was to evaluate a combined therapeutic intervention, including the dual endothelin receptor antagonist bosentan, in patients with carcinoid heart disease (CaHD). "
4.	Atrial Natriuretic Factor (ANF)IBA 04/15/1989 - "This study demonstrates the predictive value of serial determinations of plasma ANP in carcinoid heart disease. "
5.	bosentan (Tracleer)FDA Link 01/01/2010 - "Evaluation of treatment with bosentan in patients with carcinoid heart disease: single center study." 01/01/2010 - "The primary aim of this study was to evaluate a combined therapeutic intervention, including the dual endothelin receptor antagonist bosentan, in patients with carcinoid heart disease (CaHD). "
6.	fluorodopa F 18IBA 01/01/2014 - "This study evaluates the prevalence of cardiac metastases in patients with serotonin producing neuroendocrine tumours (NET), examined with 18F-FDOPA PET/CT, and the relationship of these metastases to the presence of carcinoid heart disease (CHD) based on echocardiography. "
7.	Octreotide (Sandostatin)FDA LinkGeneric 10/01/2010 - "We could performed surgical treatment of carcinoid heart disease safely in the perioperative presence of octreotide." 05/01/2013 - "In the included case reports, carcinoid crises were managed effectively using octreotide 25-500 μg iv. Previous exposure to octreotide and carcinoid heart disease may warrant the need for higher doses. " 05/01/2013 - "A retrospective chart review of 89 patients with carcinoid heart disease reported octreotide doses of 25-54,000 μg to treat carcinoid crises, although neither crisis symptoms nor outcomes were described. " 10/01/2011 - "After 12 months of treatment with octreotide LAR, symptom resolution or improvement was seen in 60%, 48%, 48%, and 30% of patients with flushing, diarrhea, bronchoconstriction, and carcinoid heart disease, respectively. " 11/01/2007 - "We reviewed the effects of vasopressors and aprotinin on octreotide administration and mortality by univariate analysis in 100 consecutive cases of cardiac surgery for carcinoid heart disease from 1985 to 2003. "
8.	Hydroxyindoleacetic AcidIBA 10/28/2014 - "The biochemical burden of disease, in particular baseline plasma 5-HIAA concentration, is independently associated with carcinoid heart disease progression and death. " 04/15/2011 - "5-HIAA levels of ≥ 300 to 599, 600 to 899, and > 900 μmol/24 hours conferred 2.74, 3.16, and 3.40 times the risk of progression of carcinoid heart disease, respectively. " 06/01/2010 - "The correlations were strong between urinary 5-hydroxyindoleacetic acid (5-HIAA) and the right-sided carcinoid heart disease score (r = 0.75, p <0.0001), between urinary 5-HIAA and the left-sided carcinoid heart disease score (r = 0.83, p = 0.001), and between urinary 5-HIAA and the overall carcinoid heart disease score (r = 0.84, p <0.0001). " 04/15/2011 - "In conclusion, a 5-HIAA level ≥ 300 μmol/24 hours and ≥ 3 flushing episodes per day are predictors of the development or progression of carcinoid heart disease." 04/15/2011 - "Independent predictors of the development or progression of carcinoid heart disease were a 5-HIAA level ≥ 300 μmol/24 hours and ≥ 3 episodes of flushing per day. "
9.	Chromogranin AIBA 01/01/2009 - "Distant metastases, urinary 5-hydroxyindoleacetic acid ratio > or =3.7 times the upper limit of normal, chromogranin A ratio > or =6.2 times the upper limit of normal, age > or =64, male gender, carcinoid heart disease, and Ki-67 > or =5% were associated with decreased survival. " 01/01/2010 - "20,000 patients) to develop a nomogram from 15 variables demonstrated to provide significant multivariate HRs. These included age, gender, ethnicity, symptoms, urinary 5-hydroxyindoleacetic acid, plasma chromogranin A, liver function tests, tumor size, invasion, metastasis, histology, Ki-67 index, carcinoid heart disease and therapy (surgery or long-acting somatostatin analogs). " 03/01/2005 - "Adverse clinical indicators are the malignant carcinoid syndrome, carcinoid heart disease, and high concentrations of the tumor markers, urinary 5-HIAA and plasma chromogranin A."
10.	Biological Markers (Surrogate Marker)IBA 01/01/2013 - "The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study." 09/09/2010 - "Is carcinoid heart disease associated with biochemical markers of disease severity?" 01/01/2013 - "We sought to evaluate the discriminatory utility of diagnostic biomarkers in determining the presence and severity of carcinoid heart disease in patients with metastatic neuroendocrine tumors. " 11/01/2009 - "There is also a specific description of the properties of the most important biochemical markers and 2 complications, bone metastasis and carcinoid heart disease, from the biochemical point of view." 01/01/2013 - "NT-proBNP and plasma 5HIAA are both sensitive and specific biomarkers for the presence of carcinoid heart disease whereas only NT-proBNP is moderately correlated with disease severity."

Therapies and Procedures

1.	Prostheses and Implants (Prosthesis) 07/01/1996 - "A case of successful tricuspid valve replacement with a mechanical prosthesis and pulmonary valvulotomy for carcinoid heart disease is reported. " 08/01/1992 - "Between 1982 and 1989, 10 patients with carcinoid heart disease underwent tricuspid valve replacement with a mechanical prosthesis at our institution. "
2.	Heterologous Transplantation (Xenotransplantation) 01/01/1981 - "Porcine heterograft valve replacement in carcinoid heart disease." 10/01/1994 - "A woman who had carcinoid syndrome and carcinoid heart disease underwent tricuspid and pulmonary valve replacements with a xenograft and a cryopreserved allograft, respectively. "
3.	Surgical Instruments (Clip) 04/15/2014 - "As haemodynamically significant carcinoid heart disease may be clinically silent, specific and individualised considerations must be made as to the most appropriate clinical criteria and time point at which surgical valve replacement should be undertaken in patients with carcinoid heart disease. " 06/01/2012 - "Carcinoid heart disease: outcomes after surgical valve replacement."
4.	Drug Therapy (Chemotherapy) 11/01/1984 - "The principal cardiac effects of noncardiac tumors include the direct results of metastases to the heart or lungs, the indirect effects of circulating tumor products (causing nonbacterial thrombotic endocarditis, myeloma-associated amyloidosis, pheochromocytoma-associated cardiac hypertrophy and myofibrillar degeneration, and carcinoid heart disease), and the undesired cardiotoxicities of chemotherapy and radiotherapy." 03/13/2003 - "Serotonin is related to the progression of carcinoid heart disease, and the risk of progressive heart disease is higher in patients who receive chemotherapy than in those who do not."
5.	Bioprosthesis 01/01/2016 - "Transcatheter pulmonary and tricuspid valve-in-valve replacement for bioprosthesis degeneration in carcinoid heart disease." 11/01/1985 - "Two female patients with carcinoid heart disease, ages 56 and 32 years, underwent pulmonic valve resection surgery and tricuspid valve replacement with a porcine bioprosthesis. "